Skip to Content

Swedish Orphan Biovitrum AB SOBI Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SOBI

Valuation
Currency in SEK
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Sobi's Expanding Hematology and Immunology Portfolio Could Help Build a Moat

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Karen Andersen, CFA |

As recently as 2016, Swedish Orphan Biovitrum, or Sobi, was largely a specialty pharmaceutical firm in-licensing rights to market drugs in Europe. Since then, the successful launches of hemophilia drugs Elocta and Alprolix in Europe and other international markets and several acquisitions and collaborations have expanded Sobi's business geographically (to the U.S.) and into new therapeutic areas (in immunology and hematology). Sobi recent deals to acquire rights to immunology drugs (Astra's Synagis and nirsevimab, Novimmune's Gamifant, Apellis' Aspaveli/pegcetacoplan) and new hematology drugs (Dova's platelet drug Doptelet, ADC's blood cancer drug Zynlonta) help bolster long-term growth prospects. We think Sobi is taking the right steps to diversify and boost long-term growth.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SOBI

Company Profile SOBI

Business Description

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition). In 2020, new collaborations brought rights to gout drug pegadricase and complement-mediated disease drug Aspaveli.

Contact
Tomtebodavagen 23 A, Solna
Stockholm, SE-112 76, Sweden
T +46 86972000
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 1,569